Neurolymphomatosis (NL) is a rare clinical entity characterized by infiltration of peripheral nerves, nerve roots, plexus, or cranial nerves by malignant lymphocytes.
proportions of 46% and 24% respectively. NL is a challenging diagnosis but contemporary imaging techniques frequently detect the relevant neural invasion. An aggressive multimodality therapy can prevent neurological deterioration and is associated with a prolonged survival in a subset of patients.
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Introduction:
The term neurolymphomatosis (NL) encompasses nerve infiltration by neurotropic neoplastic cells in the setting of an unknown or a known hematologic malignancy. It is a rare neurologic manifestation of non-Hodgkin lymphoma (NHL) and leukemia with a poorly defined incidence. The most comprehensive review identified 72 cases of NL caused by NHL that were reported during a 28 year period 1 . The majority of patients with NL described in the literature suffered from NHL and in that setting, NL appears to represent a unique subtype of extranodal disease. However, nerve infiltrating disease may occur rarely in leukemia [2] [3] [4] and therefore, the present study assessed this clinical entity in patients with either NHL or leukemia.
The typical manifestations of NL are of a neuropathy that may affect peripheral nerves, nerve roots, plexus, or cranial nerves. The most common presentations include painful peripheral neuropathy or radiculopathy, cranial neuropathy, painless polyneuropathy and peripheral mononeuropathy or a mononeuropathy multiplex.
Successful therapy is contingent upon the recognition of this unique neurological
complication, yet the diagnosis is difficult and often elusive. Because NL is rare, there is limited information available on mode of presentation, clinical course, the yield of diagnostic procedures and response to therapy. As well, the survival following diagnosis and treatment is poorly characterized as it has never been reported in a systematic study. peripheral nerves occurs in both NHL and leukemia, the current study investigated both conditions under the common term of NL.
Methods:
A retrospective chart review was conducted by the IPCG investigators to collect information on HIV seronegative adult patients whose final diagnosis was compatible with the definition of clinical neuropathy characterized by infiltration of malignant lymphocytes. As this study is retrospective inclusion of patients was based on final diagnosis of NL that often required the full perspective of the course of neurologic manifestations and the related diagnostic workup. Eligible were patients with neoplasms categorized as either lymphoma or leukemia. Other hematologic malignancies were excluded. Eligibility criteria included patients whose clinical manifestation was consistent with either a primary NL, defined as NL that is the first manifestation of the hematologic malignancy, or patients with secondary NL, in which NL is a site of relapse or progression of a previously diagnosed lymphoma or leukemia. In principle, NL was defined as neuropathy which is characterized by infiltration of malignant cells. Yet, manifestation of either cranial neuropathy or cauda equina involvement in the presence of positive cytology was not considered as NL unless evidence existed for intradural as well as extradural infiltration of the affected nerves or alternatively, additional data indicated that malignant infiltration of either peripheral nerves and/or neural plexi has also developed. Malignant infiltration of nerve structures that occurred in the set-up of a bulky disease that entrapped and infiltrated the neural elements was excluded. In primary NL infiltration of the affected neural structure had to be proved by a biopsy or at autopsy. In secondary NL the diagnosis required exclusion of other causes of neuropathy, presence of positive imaging findings that detected specific neural involvement and evidence for disease progression. If diagnosis remained in doubt a biopsy of the affected structure was required or otherwise autopsy findings indicated the final diagnosis. Kaplan-Meier product-limit methods 6 and comparisons between primary and secondary NL were examined by the log-rank test.
Results:
Information on a total of 50 patients was assembled. NL affected more than one anatomic structure in 29 (58%) patients (table 1, figure   1A -C). Peripheral nerves were the most frequently involved site while spinal, cranial nerve involvement and neural plexus infiltration occurred at a similar rate. The manifestation of painful neuropathy was recorded in 38 (76%) patients with sensorimotor neuropathy being the most common type (36 cases). Notwithstanding, the infiltrative nature of NL, pure motor neuropathy was described in 20% of the patients and pure sensory neuropathy was noted in a single patient.
The diagnostic modalities included CSF analysis (in 45 patients), imaging studies that were reported for all patients, and nerve biopsy that was obtained in 26 (52%) of the patients (table 2) 
Therapeutic management and outcome:
Treatment was administered to 47 (90%) patients with NL (table 2) . Treatment varied, with systemic chemotherapy given to 33 (70%), intra-CSF chemotherapy to 23 (49%), When survival of patients with primary NL was compared to survival of secondary NL no statistically significant difference was observed (p=0.129) although the median survival of the 13 patients with primary NL was 20 months and that of secondary NL was 8 months (figure 2B).
Discussion:
Diagnosis of NL requires integration of clinical presentation (symptoms/signs), imaging findings and pathological data obtained from neural, extraneural tissue and the CSF. A high index of suspicion and familiarity with the clinical manifestations of NL is necessary. As it is a rare manifestation of hematologic malignancies, diagnosis is often delayed and its incidence remains unknown.
The current series is the largest detailed series ever collected. It describes the presentation, treatment and outcome of 50 NL cases that were diagnosed over a 16 year period (group C, Lastly, it may signify a trend in the biological behavior of hematologic malignancies related to a selection of specific neurotropic clones associated with either more aggressive treatment or longer survival. In order to clarify whether any of the above might have had an impact on our findings we have tried to compare the current series to previous publications (groups A and B). Group B corresponds to the period of diagnosis of the greater fraction of our patients (group C).
Diagnostic modalities:
Clinically, NL mimics nonneoplastic and paraneoplastic neuropathies. Clinical findings that suggest NL, as opposed to remote effects or inflammatory processes, include severe pain, asymmetric distribution, and rapid evolution. Painful neuropathy predominated in our series and was common in previously published cases (table 1) .
Regardless, the diagnosis is elusive and in 46% of group-A patients (identified early in the time period studied), the precise diagnosis was established only at autopsy. In the present case series and in group B from the literature (table 2) NL was more often detected ante mortem with diagnosis at autopsy reported in only 8 and 5% of cases respectively. This phenomenon of a decrease in the rate of post mortem diagnosis is likely related to the improved resolution of current imaging techniques that can detect affected neural structures with increased precision.
Of all diagnostic tools, imaging studies are of greatest clinical utility. All our patients were evaluated by one or more imaging techniques, the majority (94%) by MRI. MRI reveals nerve or root enlargement with or without contrast enhancement and oftentimes involvement of neural plexus (brachial or lumbar) that is more difficult to detect 1, [7] [8] [9] [10] [11] [12] [13] [14] ( figure 1C) . MRI findings are not specific for NL and might sometimes be seen in acute or chronic inflammatory radiculoneuropathies, in neurofibromatosis, in inflammatory pseudotumor and in malignant tumors of the peripheral nerve sheath.
Interpretation of imaging studies in the context of clinical manifestations and laboratory studies is necessary. MRI yields abnormal findings in almost 80% of PET-CT appears to be a highly sensitive diagnostic method facilitating identification of NL based on our experience and that reported in the literature (group-B in table 2, figure 1A, 1B, 1F) . Altogether, the reported experience is of 40 NL patients evaluated by PET-CT amongst which 87.5% were positive studies. Although the total number of reported cases diagnosed by PET-CT is still small, positive findings are highly suggestive of the diagnosis of NL particularly in patients with a known history of hematologic malignancy. Together with MRI findings, PET-CT may define the best target for a biopsy, if one is indicated, especially in the instance of primary NL.
Although the majority of our patients were evaluated by multiple diagnostic modalities (table 2) , biopsy of an affected nerve was indicated for pathological confirmation in 52% of the patients. The diagnostic yield of the biopsy was high (88%) (table 2) and was similar to the rate previously described in the literature (table 2, group A and B).
Therefore, if imaging and CSF findings are non-conclusive a nerve biopsy presents a reasonable approach if the risk does not outweigh the expected benefit.
Treatment and outcome:
There is no known standard treatment for NL and therefore, optimal management is ill defined. Treatment of NL consists of either chemotherapy alone or combined with radiotherapy. In order to select the appropriate therapy knowledge of the extent of systemic and nervous system involvement is essential. NL involves roots within, as well as beyond, the borders of the subarachnoid space and thus intra-CSF chemotherapy and standard craniospinal radiation fields will not treat all of the involved areas. Systemic chemotherapy is critical to address the multiple sites of involvement.
In the current series, 90% of the patients were treated, a rate that appears higher than that reported in the literature (groups A and B in table 2). This is probably related to the fact that our retrospective chart review specifically requested
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information on therapeutic management. The information collected from the literature contains inadequate information on clinical management as some of the case reports addressed only the unusual neuroimaging findings 8, 11, [14] [15] [16] [17] [18] [19] [20] [21] .
In the current series, the majority of patients (70%) were managed by systemic chemotherapy. The most effective regimen is unknown and the selection is often based on protocols used to treat CNS involvement by malignant lymphoma. Many centers employed intravenous high-dose methotrexate, either alone or in combination with other drugs and particularly with high-dose cytarabine.
Methotrexate is effective against lymphoma affecting the nervous system and when given in high doses can penetrate the blood-brain and blood-nerve barrier. Any other choice of chemotherapy must also meet those criteria. However, in our series approximately 30% of treated patients did not receive systemic chemotherapy due to the fact that NL represented relapse of a chemoresistant disease.
Radiotherapy has a limited role in the treatment of NL due to involvement of multiple sites, affecting both the CNS and the peripheral nervous system. Extensive radiation fields are poorly tolerated in most patients but limited-field radiotherapy can be very effective in relieving unremitting neuropathic pain attributed to a particular nerve, plexus or nerve root.
Clinical improvement (functional recovery, reduction of pain), as well as radiographic resolution (improvement of nerve root enlargement and enhancement or normalization of FDG-PET uptake) has been observed in 50 to 70% of treated patients (table 2) (figure 1D-E, 1F-G). Standardized criteria to measure response are not available and therefore no recommendations can be made from regarding treatment response.
There is no previous information on overall survival of patients with NL. The median survival from diagnosis of NL in our series was 10 months with 36-month survival proportion of 24%. These data indicate that an aggressive multimodality therapeutic
For personal use only. on . by guest www.bloodjournal.org From approach can achieve long term survival in some patients. The trend toward longer median survival observed in primary NL likely reflects the fact that NL was the presenting manifestation of the malignant disease unlike in secondary NL.
Nonetheless, long term survival was observed in secondary NL with one in four of all patients alive at 3 years.
In conclusion, it appears that NL is more frequently diagnosed in recent years. It is likely related to increased awareness of the disease and an enhanced rate of diagnosis due to the extensive use of contemporary imaging techniques that accurately localize abnormal process affecting neural structures. Early recognition and treatment of this rare neurological manifestation of lymphoma and leukemia may improve outcome.
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